Patrick Petignat

Prof. Patrick Petignat

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
MDMila Donker
Mila Donker
GTGeertjan van Tienhoven
Geertjan van Tienhoven
MSMarieke E Straver
Marieke E Straver
PMPhilip Meijnen
Philip Meijnen
CVCornelis J H van de Velde
Cornelis J H van de Velde
EREmiel J T Rutgers
Emiel J T Rutgers

1 November 2000 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
YVY. Vial
Y. Vial
PPPatrick Petignat
Patrick Petignat
PHP. Hohlfeld
P. Hohlfeld

1 May 2007 in Gynecologic Oncology
Verified
Journal Article
Closed access
PPPatrick Petignat
Patrick Petignat
DFDaniel L. Faltin
Daniel L. Faltin
IBIlan Bruchim
Ilan Bruchim
MTMartin R. Tramèr
Martin R. Tramèr
EFEduardo Franco
Eduardo Franco
FCFrançois Coutlée
François Coutlée

1 January 2015 in World Journal of Clinical Oncology
Verified
Journal Article
Open access
RCRosa Catarino
Rosa Catarino
PPPatrick Petignat
Patrick Petignat
GDGabriel Dongui
Gabriel Dongui
PVPierre Vassilakos
Pierre Vassilakos
Cervical cancer (CC) represents the fourth most common malignancy affecting women all over the world and is the second most common in developing areas. In these areas, the burden from disease remains important because of the difficulty in implementing cytology-based screening programmes. The main obstacles inherent to these countries are poverty and a lack of healthcare infrastructures and trained practitioners. With the availability of new technologies, researchers have attempted to find new strategies that are adapted to low- and middle-income countries (LMIC) to promote early diagnosis of cervical pathology. Current evidence suggests that human papillomavirus (HPV) testing is more effective than cytology for CC screening. Therefore, highly sensitive tests have now been developed for primary screening. Rapid molecular methods for detecting HPV DNA have only recently been commercially available. This constitutes a milestone in CC screening in low-resource settings because it may help overcome the great majority of obstacles inherent to previous screening programmes. Despite several advantages, HPV-based screening has a low positive predictive value for CC, so that HPV-positive women need to be triaged with further testing to determine optimal management. Visual inspection tests, cytology and novel biomarkers are some options. In this review, we provide an overview of current and emerging screening approaches for CC. In particular, we discuss the challenge of implementing an efficient cervical screening adapted to LMIC and the opportunity to introduce primary HPV-based screening with the availability of point-of-care (POC) HPV testing. The most adapted screening strategy to LMIC is still a work in progress, but we have reasons to believe that POC HPV testing makes part of the future strategies in association with a triage test that still needs to be defined.

2 September 2016 in Human Reproduction Update
Verified
Journal Article
Closed access
PDF file
NPNicola Pluchino
Nicola Pluchino
JWJean-Marie Wenger
Jean-Marie Wenger
PPPatrick Petignat
Patrick Petignat
RTReshef Tal
Reshef Tal
MBMylene Bolmont
Mylene Bolmont
FBFrancesco Bianchi-Demicheli
Francesco Bianchi-Demicheli
BACKGROUND Sexual function is an important aspect of health and quality of life and is influenced by both medical conditions and health-care interventions, especially when gynecologic disorders are involved. Coital pain is among the main factors that affect sexual functioning, and this symptom is reported by almost half of women suffering from endometriosis. However, sexuality is a complex phenomenon driven by social, psychological and biological/hormonal factors and the presence of endometriosis might further affect domains of sexual function and the quality of a sexual relationship. OBJECTIVE AND RATIONALE The objective of this report is to review the current state of knowledge on the impact that endometriosis and its treatments have on the sexual function of women and their sexual partners. SEARCH METHODS A systematic literature search was performed to identify studies evaluating sexual function in endometriosis patients, and a narrative analysis of results is presented. The review discusses relevant quantitative and qualitative studies analyzing the effect of endometriosis and its hormonal and surgical treatments on measures of sexual function and quality of sexual relationship. OUTCOMES Endometriosis negatively affects different domains of sexual function, and the presence of dyspareunia is not the only determinant of sexual health in these women. Chronic pelvic pain, advanced stages of disease and the presence of physical and mental comorbidities affect sexual function, as well as personality traits and women's expectations. Although a number of studies have evaluated the effect of surgery and hormonal treatment on deep dyspareunia, overall sexual function and quality of the relationship with the partner are often under-investigated. WIDER IMPLICATIONS Multiple clinical and personal determinants affect sexual function in women with endometriosis, with potentially negative consequences on the sexual function of partners and quality of the relationship. Additional prospective and longitudinal investigations are warranted using specific instruments to analyze biopsychosocial variables of sexual pain in endometriosis patients and the effects that actual treatments have on measures of quality of sexual function and relationship.

11 October 2007 in BMJ
Verified
Journal Article
Closed access
PDF file
PPPatrick Petignat
Patrick Petignat
MRMichel Roy
Michel Roy
Sources and selection criteriaWe searched the literature to identify all relevant articles published from 1966 to March 2007 (PubMed and Cochrane database) using a combination of the terms “cervical cancer”, “diagnosis”, and “management”. Variables of interest were cervical cancer, surgery, chemotherapy, radiotherapy, chemoradiotherapy, complications of treatment, recurrence, and follow-up. Much of the clinical management discussed in this review was based on meta-analyses, systematic reviews, and phase III randomised controlled trials (RCTs).